LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Pfizer

Gesloten

SectorGezondheidszorg

25.17 0.28

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.13

Max

25.21

Belangrijke statistieken

By Trading Economics

Inkomsten

-45M

2.9B

Verkoop

938M

15B

K/W

Sectorgemiddelde

13.005

34.427

EPS

0.78

Dividendrendement

6.92

Winstmarge

19.982

Werknemers

81,000

EBITDA

266M

5.3B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+13.72% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

6.92%

2.47%

Volgende Winsten

28 okt 2025

Volgende dividenddatum

2 sep 2025

Volgende Ex Dividend datum

7 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

6B

140B

Vorige openingsprijs

24.89

Vorige sluitingsprijs

25.17

Nieuwssentiment

By Acuity

52%

48%

294 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Pfizer Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 aug 2025, 11:34 UTC

Winsten

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

5 aug 2025, 20:44 UTC

Winsten

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 aug 2025, 18:20 UTC

Winsten

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 aug 2025, 18:17 UTC

Winsten

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 aug 2025, 16:04 UTC

Marktinformatie

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5 aug 2025, 15:25 UTC

Winsten

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 aug 2025, 13:56 UTC

Winsten

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 aug 2025, 11:43 UTC

Winsten

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5 aug 2025, 11:27 UTC

Winsten

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug 2025, 10:57 UTC

Winsten

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5 aug 2025, 10:55 UTC

Winsten

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug 2025, 10:53 UTC

Winsten

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5 aug 2025, 10:51 UTC

Winsten

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

5 aug 2025, 10:50 UTC

Winsten

Pfizer: Expects to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

5 aug 2025, 10:49 UTC

Winsten

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2025 >PFE

5 aug 2025, 10:49 UTC

Winsten

Pfizer Now Sees 2025 Effective Tax Rate on Adjusted Income About 13%; Had Seen About 15% >PFE

5 aug 2025, 10:48 UTC

Winsten

Pfizer Cuts Adjusted R&D Expenses View to $10.4-$11.4B From $10.7B-$11.7B >PFE

5 aug 2025, 10:48 UTC

Winsten

Pfizer: Guidance Absorbs Impact of Potential Price Changes This Year Based on Letter Received July 31 From President Trump >PFE

5 aug 2025, 10:47 UTC

Winsten

Pfizer: Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

5 aug 2025, 10:46 UTC

Winsten

Pfizer Had Seen 2025 Adjusted EPS $2.80-$3.00 >PFE

5 aug 2025, 10:45 UTC

Winsten

Pfizer Raises 2025 EPS Guidance >PFE

5 aug 2025, 10:45 UTC

Winsten

Pfizer 2Q EPS 51c >PFE

5 aug 2025, 10:45 UTC

Winsten

Pfizer Sees FY Adj EPS $2.90-Adj EPS $3.10 >PFE

5 aug 2025, 10:45 UTC

Winsten

Pfizer 2Q Adj EPS 78c >PFE

5 aug 2025, 10:45 UTC

Winsten

Pfizer 2Q Rev $14.7B >PFE

5 aug 2025, 10:45 UTC

Winsten

Pfizer Sees FY Rev $61B-$64B >PFE

4 aug 2025, 15:26 UTC

Winsten

Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason. -- Barrons.com

30 jul 2025, 18:36 UTC

Winsten

UPS Stock Joins 7% Yielders in S&P 500. Here's Who Else Is in the Club. -- Barrons.com

9 jul 2025, 09:17 UTC

Populaire aandelen

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

10 jun 2025, 12:18 UTC

Winsten

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Peer Vergelijking

Prijswijziging

Pfizer Prognose

Koersdoel

By TipRanks

13.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.59 USD  13.72%

Hoogste 33 USD

Laagste 24 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pfizer - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

6

Buy

12

Hold

0

Sell

Technische score

By Trading Central

22.855 / 23.85Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

294 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.